$4.04
+4.10%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$3.98
From 52W high−22.62%
Volume1.35M
Market cap$800.19M
P/E (TTM)5.1x
P/S (TTM)4.4x
Div yield—
Key dataNov 4, 2026
Open
$3.98
From 52W high
−22.62%
Volume
1.35M
Market cap
$800.19M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
4.6x
P/E (TTM)
5.1x
RSI (14)
32.1
MomentumView details →
1D Return
+4.10%
YTD Return
−18.31%
SummaryUpdated Jun 1, 2026
Arbutus Biopharma Corporation (NASDAQ:ABUS) is a biopharmaceutical company founded in 2007 and headquartered in Warminster, Pennsylvania. Originally known as Tekmira Pharmaceuticals Corporation, the company changed its name to Arbutus Biopharma in July 2015. The company focuses on developing novel therapeutics primarily for chronic Hepatitis B virus infection, with additional research programs targeting coronaviruses including SARS-CoV-2. Arbutus has evolved from a broader drug delivery platform company into a specialized biotechnology firm with a concentrated focus on developing what it aims to be a functional cure for chronic Hepatitis B.
Similar companies
Latest newsMore news →
The U.S. Food and Drug Administration lifted the clinical hold on Arbutus Biopharma’s IND application for AB-101, allowing additional clinical development in the United States.13d agoArbutus Biopharma Corporation announced preliminary results of its modified Dutch auction tender offer to purchase for cancellation up to US$230 million in value of its common shares, with a tender price range of US$5.00 to US$5.75 per share, expiring September 29, 2026.35d ago